Abstract

This article presents supplementary data for the research article by Yotsukura et al. entitled “Prognostic impact of cancer-associated active fibroblasts and invasive architectural patterns on early-stage lung adenocarcinoma” [1], which presented the postoperative prognosis for early-stage lung adenocarcinoma categorized according to histological findings. We included data of 1,032 resected cases of lung adenocarcinoma, which consisted of pathological stage IA invasive cancer and adenocarcinoma in situ resected at National Cancer Center Hospital, Tokyo, Japan, between 2007 and 2012. A pathological review was performed to assess total tumor size, size of invasion, histological subtype, lymphovascular invasion, and presence of cancer-associated active fibroblast (CAF). Tumor recurrence and overall survival were retrospectively recorded. Of the included cases, 166 (16.1%), and 866 (83.9%) were adenocarcinoma in situ and pathological stage IA, respectively. Pathological stage IA adenocarcinoma was further classified based on the histologial subtype and the presence of CAF. This data set may be useful for analyzing the postoperative prognosis of early-stage lung adenocarcinoma, in combination with detailed pathological findings including size of invasion, histological subtype, and presence of CAF.

Highlights

  • This article presents supplementary data for the research article by Yotsukura et al entitled “Prognostic impact of cancerassociated active fibroblasts and invasive architectural patterns on early-stage lung adenocarcinoma” [1], which presented the postoperative prognosis for early-stage lung adenocarcinoma categorized according to histological findings

  • This data set may be useful for analyzing the postoperative prognosis of early-stage lung adenocarcinoma, in combination with detailed pathological findings including size of invasion, histological subtype, and presence of cancer-associated active fibroblast (CAF)

  • The data were acquired from 1,032 cases of pathological stage IA lung adenocarcinoma and adenocarcinoma in situ who underwent complete resection between 2007 and 2012 at National Cancer Center Hospital, Tokyo, Japan

Read more

Summary

Data Description

The estimated 3- /5-year overall survival rates were 97.4% (95% confidence interval [CI]: 96.398.5)/97.0% (95% CI: 95.8-98.1) and 98.8% (95% CI: 97.1-100)/98.1% (95% CI: 96.0-100) for stage IA cancer and AIS, respectively. The numbers of patients at risk were 866/166 at the time of the operation, 794/160 at postoperative year 3, and 565/117 at postoperative year 5 for stage IA adenocarcinoma/AIS, respectively

Ethics Statement
Findings
Declaration of Competing Interest
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.